Notably, the HER2-positive breast cancer subtype (HER2+-BC) is particularly invasive and displays a poorer prognosis compared to hormone receptor-positive (ER+ or/and PR+) BC3. This evidence concerns the gene ERBB2 and breast carcinoma.